趙海濤，1972年生，籍貫天津市，北京協(xié)和醫(yī)院肝臟外科主任醫(yī)師，博士生導師。1989年考入北京醫(yī)科大學臨床醫(yī)學專業(yè)，1994年獲得學士學位。2001年在北京大學醫(yī)學部外科學專業(yè)攻讀碩士學位，從事臨床醫(yī)學研究。2010年在北京協(xié)和醫(yī)學院外科學專業(yè)攻讀博士學位，從事外科學研究。2010年升為副主任醫(yī)師。2017年升為主任醫(yī)師。

研究方向專注于肝癌的基礎研究與臨床應用研究，主要研究興趣在于通過高通量測序研究肝膽系統(tǒng)惡性腫瘤發(fā)病機制、基因分型，鑒定腫瘤治療靶點，應用于臨床的精準醫(yī)療轉化研究。團隊長期致力于肝膽惡性腫瘤的靶向免疫治療、基因組學、腫瘤異質性及起源重大臨床科研問題。

爆草黑丝美女|韩国19禁无遮挡啪啪无码网站|91精品国产自产精品男人的天堂|sm鞭打高潮喷水抽搐调教玩弄|果冻在线|日本大尺度吃奶呻吟视频|久久久久黄片|北条麻妃av免费观看|中文字幕一区二区人妻|亚洲最大天堂无码精品区,日韩 欧美 国产精品,国产肉丝袜在线观看,最爽无遮挡行房视频,成人H视频在线观看,糖心vlog冉冉,蜜桃产品一二三产区

1. Lin J#, Peng X#, Dong K#, Long J#, Guo X, Li H, Bai Y, Yang X, Wang D, Lu X, Mao Y, Sang X, Ji X, Zhao H*, Liang H*.Genomic characterization of co-existing neoplasia and carcinoma lesions reveals distinct evolutionary paths of gallbladder cancer. Nature Communications. 2021 Aug 6;12(1):4753. (IF=14.919)

2. Long J#, Huang S#, Bai Y#, Mao J#, Wang A, Lin Y, Yang X, Wang D, Lin J, Bian J, Yang X, Sang X*, Wang X*, Zhao H*. Transcriptional landscape of cholangiocarcinoma revealed by weighted gene coexpression network analysis., Brief Bioinform, 2021, 20(22): 224. (IF=11.622)

3. Yang X#, Hu Y#, Yang K#, Wang D#, Lin J, Long J, Xie F, Mao J, Bian J, Guan M, Pan J, Huo L, Hu K, Yang X, Mao Y, Sang X, Zhang J, Wang X*, Zhang H*, Zhao H*. Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers. J Immunother Cancer. 2021 May;9(5):e001942. (IF=13.751)

4. Lin J#, Cao Y#, Yang X#, Li G, Shi Y, Wang D, Long J, Song Y, Mao J, Xie F, Bai Y, Zhang L, Yang X, Wan X, Wang A, Guan M, Zhao L, Hu K, Pan J, Huo L, Lu X, Mao Y, Sang X, Zhang H*, Wang K*, Wang X*, Zhao H*.Mutational spectrum and precision oncology for biliary tract carcinoma. Theranostics. 2021 Mar 4;11(10):4585-4598 . (IF=11.556)

5. Lin J#, Shi J#, Guo H#, Yang X, Jiang Y, Long J, Bai Y, Wang D, Yang X, Wan X, Zhang L, Pan J, Hu K, Guan M, Huo L, Sang X, Wang K*, Zhao H*.Alterations in DNA Damage Repair Genes in Primary Liver Cancer. Clin Cancer Res. 2019 Aug 1;25(15):4701-4711. (IF=10.107)

6. Long J#, Wang A#, Bai Y#, Lin J, Yang X, Wang D, Yang X, Jiang Y, Zhao H*. Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma. EBioMedicine. 2019 Apr;42:363-374. (IF=8.143, ESI)

7. Wang A#, Wu L#, Lin J#, Han L, Bian J, Wu Y, Robson SC, Xue L, Ge Y, Sang X*, Wang W*, Zhao H*.Whole-exome sequencing reveals the origin and evolution of hepato-cholangiocarcinoma. Nature Communications. 2018 Mar 1;9(1):894. (IF=11.878)

8. Long J#, Lin J#, Wang A#, Wu L, Zheng Y, Yang X, Wan X, Xu H, Chen S, Zhao H. PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. J Hematol Oncol. 2017 Aug 3;10(1):146. (IF=7.333)

9. Yang Z, Wu L, Wang A, Tang W, Zhao Y, Zhao H*, Teschendorff AE*. dbDEMC 2.0: updated database of differentially expressed miRNAs in human cancers. Nucleic Acids Res. 2017 Jan 4;45(D1):D812-D818.  (IF=11.162)

10. Long J#, Lin J#, Wang A#, Wu L, Zheng Y, Yang X, Wan X, Xu H*, Chen S*, Zhao H*.Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis. Journal of Hepatology 2014 Oct;61(4):840-849. (IF=11.336)